Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2025)

Caribou Biosciences (CRBU) has 6 years of Capital Expenditures data on file, last reported at -$216000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures fell 104.79% year-over-year to -$216000.0 in Q4 2025; TTM through Mar 2026 was $317000.0, a 92.91% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 72.15% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$216000.0, down from $1.5 million in the prior quarter.
• Over the last five years, Capital Expenditures for CRBU reached as high as $4.8 million in Q3 2023 and fell as low as -$3.5 million in Q4 2022.
• Historically, Capital Expenditures has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• Across the five-year window, Capital Expenditures tumbled 1800.0% in 2021 and surged 3186.36% in 2022, its largest moves.
• Year by year, Capital Expenditures stood at $1.9 million in 2021, then tumbled by 287.48% to -$3.5 million in 2022, then jumped by 165.54% to $2.3 million in 2023, then surged by 97.94% to $4.5 million in 2024, then slumped by 104.79% to -$216000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$216000.0 in Q4 2025, $1.5 million in Q3 2025, and -$975000.0 in Q2 2025.